PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
1558.29%
ROE above 1.5x AVXL's 31.08%. David Dodd would confirm if such superior profitability is sustainable.
-1100416.20%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
2892.68%
ROCE above 1.5x AVXL's 27.14%. David Dodd would check if sustainable process or technology advantages are in play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.